 |
|
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences
Tian Yang, Ming-Da Wang, Xin-Fei Xu, Chao Li, Han Wu, Feng Shen
Clin Mol Hepatol. 2023;29(2):342-344. Published online 2023 Mar 16 DOI: https://doi.org/10.3350/cmh.2023.0106
|
|
Citations to this article as recorded by
 Predictive indicators of immune therapy efficacy in hepatocellular carcinoma based on neutrophil-to-lymphocyte ratio
Shengzhe Lin, Yang Wang, Xinran Cai, Yunbin Ye, Yanling Chen
International Immunopharmacology.2024; 128: 111477. CrossRef Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma
Ming-Da Wang, Yong-Kang Diao, Lan-Qing Yao, Zhong-Qi Fan, Ke-Chun Wang, Han Wu, Li-Hui Gu, Jia-Hao Xu, Chao Li, Guo-Yue Lv, Tian Yang
iLIVER.2024; 3(1): 100083. CrossRef Cell-Membrane-Coated Metal–Organic Framework Nanocarrier Combining Chemodynamic Therapy for the Inhibition of Hepatocellular Carcinoma Proliferation
Huaying Xie, Xuhua Xiao, Xiaoyuan Yi, Kunzhao Huang, Liyan Wang
Pharmaceutics.2024; 16(5): 619. CrossRef Apolipoprotein H-based prognostic risk correlates with liver lipid metabolism disorder in patients with HBV-related hepatocellular carcinoma
Yaming Liu, Zeyi Wu, Yiqun Zhao, Maochuan Zhen, Yanhong Wang, Qiusong Liu
Heliyon.2024; 10(10): e31412. CrossRef Integrated Bioinformatic Analysis Reveals the Oncogenic, Survival, and Prognostic Characteristics of TPX2 in Hepatocellular Carcinoma
Weibin Zhang, Jia Dong, Yunfei Wu, Xiangnan Liang, Lida Suo, Liming Wang
Biochemical Genetics.2024;[Epub] CrossRef
|